REGENXBIO/RGNX

$16.09

2.88%
-
1D1W1MYTD1YMAX

About REGENXBIO

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Ticker

RGNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kenneth Mills

Employees

344

Headquarters

Rockville, United States

REGENXBIO Metrics

BasicAdvanced
$769.48M
Market cap
-
P/E ratio
-$6.03
EPS
1.38
Beta
-
Dividend rate
$769.48M
1.37615
$28.80
$11.83
741.09K
2.571
-37.45%
-63.65%
-45.96%
8.527
2.217
2.468
-19.94%
7.24%
-16.42%

What the Analysts think about REGENXBIO

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 12 analysts.
147.55% upside
High $55.00
Low $21.00
$16.09
Current price
$39.83
Average price target

REGENXBIO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-282.88% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$22.2M
-23.18%
Net income
$-62.8M
1.62%
Profit margin
-282.88%
32.29%

REGENXBIO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.55%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.53
-$1.66
-$1.41
-$1.43
-
Expected
-$1.54
-$1.39
-$1.52
-$1.27
-$1.26
Surprise
-0.43%
19.86%
-7.1%
12.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for REGENXBIO stock?

REGENXBIO (RGNX) has a market cap of $769.48M as of April 23, 2024.

What is the P/E ratio for REGENXBIO stock?

The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of April 23, 2024.

Does REGENXBIO stock pay dividends?

No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next REGENXBIO dividend payment date?

REGENXBIO (RGNX) stock does not pay dividends to its shareholders.

What is the beta indicator for REGENXBIO?

REGENXBIO (RGNX) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the REGENXBIO stock price target?

The target price for REGENXBIO (RGNX) stock is $39.83, which is 147.55% above the current price of $16.09. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell REGENXBIO stock

Buy or sell REGENXBIO stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing